Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabetes and chronic kidney disease ...
International Investment's unique blend of content for the international wealth management community is now available exclusively on Investment Week. International Investment formerly served ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results